As of July 29, 2025, Dishman Carbogen Amcis Ltd (DCAL) is trading around ₹253.20, showing an intraday price range between ₹232.25 and ₹253.20. The stock opened at ₹241.15 and is currently in an uptrend with average traded price near ₹246.15. Market capitalization is approximately ₹3,970 crore. The stock has experienced volatility but appears to be gaining momentum in recent sessions with strong trading volumes.
### Price and Trend
- Recent price movement shows recovery with steady intraday gains and bullish momentum.
- The stock is trading below its 52-week high of around ₹308 but above its 52-week low of ₹155.
- Technicals indicate the stock is in an upward phase, supported by positive sentiment.
### Financial and Valuation Highlights
- DCAL’s price-to-earnings ratio tends to be low or near zero, reflecting either fluctuating profitability or losses.
- The company operates in the healthcare sector, focusing on contract research and manufacturing services (CRAMS) in pharmaceuticals.
### Outlook
The current technical trend suggests potential near-term strength if volume and price momentum sustain. However, given the mixed historic earnings and sector dynamics, monitoring quarterly results and sector developments is advisable for a clearer long-term outlook. Investors should also consider volatility and valuation metrics before positioning.
In summary, DCAL is showing signs of a bullish uptrend around ₹250–₹255 with moderate liquidity and market cap near ₹4,000 crore, suitable for investors looking for exposure in the pharmaceutical CRAMS segment with a medium risk appetite.
### Price and Trend
- Recent price movement shows recovery with steady intraday gains and bullish momentum.
- The stock is trading below its 52-week high of around ₹308 but above its 52-week low of ₹155.
- Technicals indicate the stock is in an upward phase, supported by positive sentiment.
### Financial and Valuation Highlights
- DCAL’s price-to-earnings ratio tends to be low or near zero, reflecting either fluctuating profitability or losses.
- The company operates in the healthcare sector, focusing on contract research and manufacturing services (CRAMS) in pharmaceuticals.
### Outlook
The current technical trend suggests potential near-term strength if volume and price momentum sustain. However, given the mixed historic earnings and sector dynamics, monitoring quarterly results and sector developments is advisable for a clearer long-term outlook. Investors should also consider volatility and valuation metrics before positioning.
In summary, DCAL is showing signs of a bullish uptrend around ₹250–₹255 with moderate liquidity and market cap near ₹4,000 crore, suitable for investors looking for exposure in the pharmaceutical CRAMS segment with a medium risk appetite.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.